Which has better earnings and valuation, WGS or PACS?

PACS Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 4.03 -$21.02M -$2.68 N/A PACS Group $5.29B 1.12 $191.54M $1.56 23.90

Is WGS or PACS more profitable?

PACS Group has a net margin of 4.49% compared to GeneDx's net margin of -17.58%. PACS Group's return on equity of 26.47% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -17.58% 9.15% 5.21% PACS Group 4.49% 26.47% 4.36%

Does the media refer more to WGS or PACS?

In the previous week, GeneDx had 26 more articles in the media than PACS Group. MarketBeat recorded 36 mentions for GeneDx and 10 mentions for PACS Group. GeneDx's average media sentiment score of 0.17 beat PACS Group's score of -0.05 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 5 Very Positive mention(s) 1 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PACS Group 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer WGS or CAI?

In the previous week, GeneDx had 33 more articles in the media than Caris Life Sciences. MarketBeat recorded 36 mentions for GeneDx and 3 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.51 beat GeneDx's score of 0.17 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 5 Very Positive mention(s) 1 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caris Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, WGS or BLLN?

Billiontoone has lower revenue, but higher earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 4.03 -$21.02M -$2.68 N/A Billiontoone $305.11M 15.72 $7.45M $0.55 189.60

Does the media prefer WGS or BLLN?

In the previous week, GeneDx had 30 more articles in the media than Billiontoone. MarketBeat recorded 36 mentions for GeneDx and 6 mentions for Billiontoone. GeneDx's average media sentiment score of 0.17 beat Billiontoone's score of -0.18 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 5 Very Positive mention(s) 1 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Billiontoone 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, WGS or SHC?

Sotera Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeneDx $427.54M 4.03 -$21.02M -$2.68 N/A Sotera Health $1.19B 3.80 $77.94M $0.41 38.63

Is WGS or SHC more profitable?

Sotera Health has a net margin of 9.91% compared to GeneDx's net margin of -17.58%. Sotera Health's return on equity of 39.73% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets GeneDx -17.58% 9.15% 5.21% Sotera Health 9.91% 39.73% 7.05%

Which has better valuation & earnings, RDNT or WGS?

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RadNet $2.04B 2.17 -$18.65M -$0.18 N/A GeneDx $427.54M 4.03 -$21.02M -$2.68 N/A

Is RDNT or WGS more profitable?

RadNet has a net margin of -0.66% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.66% 2.77% 0.97% GeneDx -17.58% 9.15% 5.21%

Does the media favor RDNT or WGS?

In the previous week, GeneDx had 29 more articles in the media than RadNet. MarketBeat recorded 36 mentions for GeneDx and 7 mentions for RadNet. GeneDx's average media sentiment score of 0.17 beat RadNet's score of 0.04 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeneDx 5 Very Positive mention(s) 1 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GeneDx (WGS) Competitors

$58.08 +2.66 (+4.80%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$58.10 +0.02 (+0.03%)

As of 06:11 AM Eastern

Compare

WGS vs. PACS, CAI, BLLN, SHC, and RDNT

Should you buy GeneDx stock or one of its competitors? MarketBeat compares GeneDx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GeneDx include PACS Group (PACS), Caris Life Sciences (CAI), Billiontoone (BLLN), Sotera Health (SHC), and RadNet (RDNT). These companies are all part of the "healthcare" industry.

How does GeneDx compare to PACS Group?

GeneDx (NASDAQ:WGS) and PACS Group (NYSE:PACS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

PACS Group has a net margin of 4.49% compared to GeneDx's net margin of -17.58%. PACS Group's return on equity of 26.47% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
PACS Group	4.49%	26.47%	4.36%

GeneDx presently has a consensus price target of $86.86, indicating a potential upside of 49.55%. PACS Group has a consensus price target of $48.00, indicating a potential upside of 28.72%. Given GeneDx's higher possible upside, equities analysts plainly believe GeneDx is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, GeneDx had 26 more articles in the media than PACS Group. MarketBeat recorded 36 mentions for GeneDx and 10 mentions for PACS Group. GeneDx's average media sentiment score of 0.17 beat PACS Group's score of -0.05 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	5 Very Positive mention(s)	1 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PACS Group	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.7% of GeneDx shares are held by institutional investors. 25.2% of GeneDx shares are held by insiders. Comparatively, 70.1% of PACS Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PACS Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.03	-$21.02M	-$2.68	N/A
PACS Group	$5.29B	1.12	$191.54M	$1.56	23.90

Summary

PACS Group beats GeneDx on 8 of the 15 factors compared between the two stocks.

How does GeneDx compare to Caris Life Sciences?

GeneDx (NASDAQ:WGS) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

GeneDx has higher earnings, but lower revenue than Caris Life Sciences. GeneDx is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.03	-$21.02M	-$2.68	N/A
Caris Life Sciences	$812.03M	6.13	-$68.09M	-$7.61	N/A

GeneDx currently has a consensus target price of $86.86, suggesting a potential upside of 49.55%. Caris Life Sciences has a consensus target price of $27.56, suggesting a potential upside of 56.57%. Given Caris Life Sciences' higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Caris Life Sciences has a net margin of 3.75% compared to GeneDx's net margin of -17.58%. Caris Life Sciences' return on equity of 98.28% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Caris Life Sciences	3.75%	98.28%	48.87%

61.7% of GeneDx shares are held by institutional investors. 25.2% of GeneDx shares are held by company insiders. Comparatively, 50.0% of Caris Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, GeneDx had 33 more articles in the media than Caris Life Sciences. MarketBeat recorded 36 mentions for GeneDx and 3 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 0.51 beat GeneDx's score of 0.17 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	5 Very Positive mention(s)	1 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caris Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Caris Life Sciences beats GeneDx on 9 of the 14 factors compared between the two stocks.

How does GeneDx compare to Billiontoone?

GeneDx (NASDAQ:WGS) and Billiontoone (NASDAQ:BLLN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Billiontoone has a net margin of 0.00% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Billiontoone	N/A	N/A	N/A

In the previous week, GeneDx had 30 more articles in the media than Billiontoone. MarketBeat recorded 36 mentions for GeneDx and 6 mentions for Billiontoone. GeneDx's average media sentiment score of 0.17 beat Billiontoone's score of -0.18 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	5 Very Positive mention(s)	1 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Billiontoone	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Billiontoone has lower revenue, but higher earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.03	-$21.02M	-$2.68	N/A
Billiontoone	$305.11M	15.72	$7.45M	$0.55	189.60

61.7% of GeneDx shares are owned by institutional investors. 25.2% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

GeneDx currently has a consensus price target of $86.86, indicating a potential upside of 49.55%. Billiontoone has a consensus price target of $125.29, indicating a potential upside of 20.14%. Given GeneDx's stronger consensus rating and higher possible upside, research analysts clearly believe GeneDx is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

GeneDx beats Billiontoone on 9 of the 14 factors compared between the two stocks.

How does GeneDx compare to Sotera Health?

GeneDx (NASDAQ:WGS) and Sotera Health (NASDAQ:SHC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

GeneDx presently has a consensus price target of $86.86, indicating a potential upside of 49.55%. Sotera Health has a consensus price target of $20.29, indicating a potential upside of 28.07%. Given GeneDx's higher possible upside, analysts clearly believe GeneDx is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

61.7% of GeneDx shares are held by institutional investors. Comparatively, 91.0% of Sotera Health shares are held by institutional investors. 25.2% of GeneDx shares are held by company insiders. Comparatively, 15.4% of Sotera Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, GeneDx had 36 more articles in the media than Sotera Health. MarketBeat recorded 36 mentions for GeneDx and 0 mentions for Sotera Health. GeneDx's average media sentiment score of 0.17 beat Sotera Health's score of 0.00 indicating that GeneDx is being referred to more favorably in the media.

Company	Overall Sentiment
GeneDx	Neutral
Sotera Health	Neutral

Sotera Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	4.03	-$21.02M	-$2.68	N/A
Sotera Health	$1.19B	3.80	$77.94M	$0.41	38.63

GeneDx has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Sotera Health has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Sotera Health has a net margin of 9.91% compared to GeneDx's net margin of -17.58%. Sotera Health's return on equity of 39.73% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Sotera Health	9.91%	39.73%	7.05%

Summary

Sotera Health beats GeneDx on 10 of the 16 factors compared between the two stocks.

How does GeneDx compare to RadNet?

RadNet (NASDAQ:RDNT) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.17	-$18.65M	-$0.18	N/A
GeneDx	$427.54M	4.03	-$21.02M	-$2.68	N/A

RadNet has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

77.9% of RadNet shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 5.6% of RadNet shares are held by insiders. Comparatively, 25.2% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, GeneDx had 29 more articles in the media than RadNet. MarketBeat recorded 36 mentions for GeneDx and 7 mentions for RadNet. GeneDx's average media sentiment score of 0.17 beat RadNet's score of 0.04 indicating that GeneDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeneDx	5 Very Positive mention(s)	1 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

RadNet currently has a consensus price target of $87.43, indicating a potential upside of 55.57%. GeneDx has a consensus price target of $86.86, indicating a potential upside of 49.55%. Given RadNet's stronger consensus rating and higher probable upside, research analysts plainly believe RadNet is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

RadNet has a net margin of -0.66% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.66%	2.77%	0.97%
GeneDx	-17.58%	9.15%	5.21%

Summary

RadNet and GeneDx tied by winning 8 of the 16 factors compared between the two stocks.

Get GeneDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WGS vs. The Competition

Export

Metric	GeneDx	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.65B	$8.69B	$6.45B	$12.38B
Dividend Yield	N/A	1.73%	2.69%	5.83%
P/E Ratio	-21.67	23.42	24.66	23.99
Price / Sales	4.03	18.08	526.33	107.23
Price / Cash	24.18	98.97	44.82	54.51
Price / Book	5.51	5.71	10.72	6.50
Net Income	-$21.02M	$174.80M	$3.56B	$336.88M
7 Day Performance	2.94%	0.15%	0.94%	-0.16%
1 Month Performance	22.76%	1.54%	0.36%	0.76%
1 Year Performance	-36.11%	8.61%	29.67%	28.49%

GeneDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WGS GeneDx	4.6152 of 5 stars	$58.08 +4.8%	$86.86 +49.5%	-27.1%	$1.65B	$427.54M	N/A	1,300	Trending News Analyst Forecast
PACS PACS Group	3.8491 of 5 stars	$35.35 -1.5%	$48.00 +35.8%	+192.0%	$5.68B	$5.29B	22.66	47,455	News Coverage Insider Trade
CAI Caris Life Sciences	4.4288 of 5 stars	$17.86 -0.7%	$27.56 +54.3%	N/A	$5.08B	$812.03M	N/A	1,846
BLLN Billiontoone	3.5994 of 5 stars	$99.38 -1.3%	$125.29 +26.1%	N/A	$4.63B	$305.11M	180.69	620	Gap Down
SHC Sotera Health	4.0143 of 5 stars	$15.46 -3.6%	$20.29 +31.2%	+42.8%	$4.57B	$1.16B	37.71	3,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WGS) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGS) Competitors